Non-Hodgkin Lymphoma | Specialty

Dr. Rosenthal on FDA Approval of Ibrutinib in Marginal Zone Lymphoma

January 20th 2017

Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses the FDA approval of of ibrutinib (Imbruvica) as a treatment for patients with marginal zone lymphoma (MZL).

FDA Approves Ibrutinib for Marginal Zone Lymphoma

January 19th 2017

The FDA has granted an accelerated approval to ibrutinib as a treatment for patients who require systemic therapy with marginal zone lymphoma following at least one prior anti-CD20-based therapy, based on findings from a single-arm phase II study.

Frontline Ibrutinib Benefit Sustained in Pivotal CLL Trial Update

January 17th 2017

Danelle James, MD, discusses the updated RESONATE-2 data presented at the ASH Annual Meeting and the next steps with ibrutinib in CLL.

Younes Discusses Key ASH Data in MCL, DLBCL

January 13th 2017

The fields of mantle cell lymphoma and diffuse large B-cell lymphoma had a handful of updates presented during the 2016 ASH Annual Meeting.

The Future of Treatment of B-Cell Lymphoma

January 13th 2017

DLBCL: CAR-T as Curative Treatment/Bridge to Transplant

January 13th 2017

CAR-T Therapy for DLBCL

January 13th 2017

Relapsed/Refractory DLBCL

January 13th 2017

Maintenance Therapy for DLBCL

January 13th 2017

Treating High-Grade Lymphoma

January 13th 2017

Risk-Based Therapy for DLBCL

January 13th 2017

CAR-T Cell Therapies in CLL

January 13th 2017

Ibrutinib for CLL with Deletion 17p

January 13th 2017

Managing Ibrutinib Toxicity in CLL

January 13th 2017

Sequencing Therapies for Relapsed/Refractory CLL

January 13th 2017

The Role of Maintenance Therapy in CLL

January 13th 2017

CLL Risk Stratification and Treatment Approach

January 13th 2017

Chronic Lymphocytic Leukemia; Initiating Therapy

January 13th 2017

Emerging Therapies for Follicular Lymphoma

January 13th 2017

R2-CHOP for Relapsed Follicular Lymphoma

January 13th 2017